These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 34246651)

  • 41. ACE and SGLT2 inhibitors: the future for non-diabetic and diabetic proteinuric renal disease.
    Perico N; Ruggenenti P; Remuzzi G
    Curr Opin Pharmacol; 2017 Apr; 33():34-40. PubMed ID: 28482281
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The effect of sodium-glucose cotransporter 2 inhibitor (tofogliflozin) on renal tubular damage in diabetic patients without albuminuria.
    Shimohata H; Iwaki Y; Yamashita M; Ohgi K; Maruyama H; Takayasu M; Hirayama K; Kobayashi M
    Int Urol Nephrol; 2022 Aug; 54(8):1907-1914. PubMed ID: 34843041
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Renal outcomes with sodium-glucose cotransporters 2 inhibitors.
    Sun X; Wang G
    Front Endocrinol (Lausanne); 2022; 13():1063341. PubMed ID: 36531469
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Renal Effects of Sodium-Glucose Co-Transporter Inhibitors.
    Thomson SC; Vallon V
    Am J Cardiol; 2019 Dec; 124 Suppl 1(Suppl 1):S28-S35. PubMed ID: 31741437
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pleiotropic Effects of Sodium-Glucose Cotransporter-2 Inhibitors: Renoprotective Mechanisms beyond Glycemic Control.
    Takata T; Isomoto H
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33922132
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effects of sodium glucose co-transporter 2 inhibitors on the kidney.
    de Albuquerque Rocha N; Neeland IJ; McCullough PA; Toto RD; McGuire DK
    Diab Vasc Dis Res; 2018 Sep; 15(5):375-386. PubMed ID: 29963920
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Dapagliflozin: potential beneficial effects in the prevention and treatment of renal and cardiovascular complications in patients with type 2 diabetes.
    Fioretto P; Avogaro A
    Expert Opin Pharmacother; 2017 Apr; 18(5):517-527. PubMed ID: 28277831
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
    Perkovic V; Jardine MJ; Neal B; Bompoint S; Heerspink HJL; Charytan DM; Edwards R; Agarwal R; Bakris G; Bull S; Cannon CP; Capuano G; Chu PL; de Zeeuw D; Greene T; Levin A; Pollock C; Wheeler DC; Yavin Y; Zhang H; Zinman B; Meininger G; Brenner BM; Mahaffey KW;
    N Engl J Med; 2019 Jun; 380(24):2295-2306. PubMed ID: 30990260
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Sodium-Glucose Cotransporter-2 Inhibitors-Miracle Drugs for the Treatment of Chronic Kidney Disease Irrespective of the Diabetes Status: Lessons from the Dedicated Kidney Disease-Focused CREDENCE and DAPA-CKD Trials.
    Gohda T; Murakoshi M
    Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430228
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Sodium-Glucose Cotransporter 2 Inhibition and Diabetic Kidney Disease.
    Alicic RZ; Neumiller JJ; Johnson EJ; Dieter B; Tuttle KR
    Diabetes; 2019 Feb; 68(2):248-257. PubMed ID: 30665953
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cardioprotection conferred by sodium-glucose cotransporter 2 inhibitors: a renal proximal tubule perspective.
    Silva Dos Santos D; Polidoro JZ; Borges-Júnior FA; Girardi ACC
    Am J Physiol Cell Physiol; 2020 Feb; 318(2):C328-C336. PubMed ID: 31721613
    [TBL] [Abstract][Full Text] [Related]  

  • 52. SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation.
    Tuttle KR; Brosius FC; Cavender MA; Fioretto P; Fowler KJ; Heerspink HJL; Manley T; McGuire DK; Molitch ME; Mottl AK; Perreault L; Rosas SE; Rossing P; Sola L; Vallon V; Wanner C; Perkovic V
    Diabetes; 2021 Jan; 70(1):1-16. PubMed ID: 33106255
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effects of glucose-lowering agents on surrogate endpoints and hard clinical renal outcomes in patients with type 2 diabetes.
    Scheen AJ
    Diabetes Metab; 2019 Apr; 45(2):110-121. PubMed ID: 30477733
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Class effects of SGLT2 inhibitors on cardiorenal outcomes.
    Kluger AY; Tecson KM; Lee AY; Lerma EV; Rangaswami J; Lepor NE; Cobble ME; McCullough PA
    Cardiovasc Diabetol; 2019 Aug; 18(1):99. PubMed ID: 31382965
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Benefits of SGLT2 inhibitors combining with renin-angiotensin-system blockers on cardiovascular outcomes in chronic kidney disease patients: A systemic review and meta-analysis.
    Liu T; Li R; Wang X; Gao X; Zhang X
    Med Clin (Barc); 2022 Jul; 159(2):65-72. PubMed ID: 34872768
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Renal Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Bae JH; Park EG; Kim S; Kim SG; Hahn S; Kim NH
    Sci Rep; 2019 Sep; 9(1):13009. PubMed ID: 31506585
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Sodium-glucose cotransporter-2 inhibitors and non-steroidal mineralocorticoid receptor antagonists: Ushering in a new era of nephroprotection beyond renin-angiotensin system blockade.
    Shenoy SV; Nagaraju SP; Bhojaraja MV; Prabhu RA; Rangaswamy D; Rao IR
    Nephrology (Carlton); 2021 Nov; 26(11):858-871. PubMed ID: 34176194
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Renal effects of SGLT2 inhibitors in cardiovascular patients with and without chronic kidney disease: focus on heart failure and renal outcomes.
    Gronda EG; Vanoli E; Iacoviello M; Urbinati S; Caldarola P; Colivicchi F; Gabrielli D
    Heart Fail Rev; 2023 May; 28(3):723-732. PubMed ID: 35098383
    [TBL] [Abstract][Full Text] [Related]  

  • 59. SGLT-2 inhibitors in diabetes: a focus on renoprotection.
    Gonzalez DE; Foresto RD; Ribeiro AB
    Rev Assoc Med Bras (1992); 2020 Jan; 66Suppl 1(Suppl 1):s17-s24. PubMed ID: 31939531
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Impact of SGLT2 inhibitors on the kidney in people with type 2 diabetes and severely increased albuminuria.
    Shah N; Perkovic V; Kotwal S
    Expert Rev Clin Pharmacol; 2022 Jul; 15(7):827-842. PubMed ID: 35912871
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.